Table 3 A summary of the IC50 of artichoke components obtained from different extraction methods. The cancer types treated in each study are also included
From: Artichoke extracts in cancer therapy: do the extraction conditions affect the anticancer activity?
Component | Cancer type | IC50 | Reference |
|---|---|---|---|
Catechin hydrate | Breast cancer (MCF-7) | 127.62 μg/mL | [125] |
EGCG | Lung cancer (H661 and H1299) | 22 μM | [126] |
EGC | Lung cancer (H661 and H1299) | 22 μM | [126] |
EGCG and EGC | Lung cancer (H441 and colorectal cancer HT-29) | 40–65 μM | [126] |
EGCG | Liver (HepG2) | 0.5 mM | [127] |
Epicatechin | Liver (HepG2) | 3.0 mM | [127] |
EGCG | Breast cancer (MCF-7) | 11.2 ± 1.4 μM | [128] |
EGCG | Colorectal adenocarcinoma (HT-29) | 136.3 ± 2.1 μM | [128] |
Myricetin | Ovarian cancer (A2780 and OVCAR3) | 25 μM | [129] |
Myricetin | Liver (HCC) | 25 μM | [130] |
Taxifolin (TAX) | Colon (HCT116) | 51.3 μM (for 24 h) 29.9 μM (for 48 h) | [131] [132] |
Taxifolin (TAX) | Colon (HT29) | 66.1 μM (for 24 h) 39.0 μM(for 48 h) | [131] [132] |
Taxifolin (TAX) | Skin scar cell carcinoma (SSCC) | 20 μM | |
Quercetin | Colon (CT-26) | 27.2 ± 1.52 μM | [133] |
Prostate (LNCaP) | 21.7 ± 2.31 μM | ||
Prostate (PC3) | 36 ± 1.98 μM | ||
Pheochromocytoma (PC12) | 11.8 ± 2.27 μM | ||
Breast (MCF-7) | 13.7 ± 2.61 μM | ||
Lymphoblastic leukaemia (MOLT-4) | 2.91 ± 0.54 μM | ||
Myeloma (U266B1) | 6.13 ± 0.73 μM | ||
Lymphoma (Raji) | 3.52 ± 0.46 μM | ||
Ovary (CHO) | 23.4 ± 3.11 μM | ||
Liver (HepG2) | 80 μM | [134] | |
Squamous cell cancer (A431 ) | 21 μM | [135] | |
Cyanidin | Renal cell carcinoma (786-o) | 120.6 μM | [136] |
Renal adenocarcinoma (ACHN) | 96.96 μM | [136] | |
Daidzein | Uroepithelial cell lines  RT4 (grade 1)  TSGH8301 (grade 2)  SCABER (grade 2)  BFTC-905 (grade 3)  T24 (grade 3)  J82 (grade 3) 40  HT-1376 (grade 3) 50 Prostate cancer  LNCaP and PC-3 Hepatoma cells (BEL-7402) Cervical (HeLa) Liver (HepG-2) Human osteosarcoma (MG-63) Lung (A549) | 20 μg/mL 40 μg/mL 40 μg/mL 30–40 μg/mL 40–50 μg/mL 40 μg/mL > 50 μg/mL 25 μg/mL 59.7 ± 8.1 μM 97.9 ± 11.3 μM > 100 μM > 100 μM > 100 μM | [137] [138] [139] |
Apigenin | Breast (MDA-MB-231 and MCF-7) Lung (A549) Hepatocellular carcinoma (SMMC-7721) Esophageal carcinoma (Eca109) | > 200 μM | [140] |
Cholangiocarcinoma (HuCCA-1) | 75 μM | [141] | |
Luteolin | Lung (A 549) Melanoma B16 T cell leukaemia cells (CCRF-HSB-2) Gastric cancer (TGBC11TKB cells) Stomach Cervix Lung Bladder Leukaemia (HL60) Squamous cell cancer (A431 ) GLC4 (lung cancer) COLO 320 (colon cancer) Gastric cancer (MKN45 and BGC823) Breast (MCF-7) Breast (MDA-MB-231) | 3.1 μM 2.3 μM 2.0 μM 1.3 μM 25 μM 27 μM 41 μM 68 μM 15 μM 19 μM 40.9 μM 32.5 μM 40 μM 25 μM 41.917 μM | [135] [135] [135] |
Morin | Leukaemia | 250 ± 40 μM | [142] |
Hesperidin | Hepatocellular carcinoma (HCC) Leukaemia (HL60) Breast (MCF-7) Osteosarcoma MG-63 cells Cervical (HeLa) | 12.5 mM 6 mM 11 μM 63.3 μM 5.275 mM | [143] [144] [145] [146] |